Kimberly Fanguy
Adult Health · West Columbia, SCNPI 1750828398
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 161 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,157, more than ten times the $100 reported in 2023.
Across 161 payments — averaging $25.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$792
- AstraZeneca$465
- TG Therapeutics, Inc.$203
- Teva Pharmaceuticals USA, Inc.$202
- UCB, Inc.$196
- Lundbeck LLC$194
- plus $2K from 22 others
What the payments were for
- Food & beverage$3,93497%
- Education$1113%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 34 | $792 |
| AstraZeneca(2 entities) | 12 | $465 |
| TG Therapeutics, Inc. | 8 | $203 |
| Teva Pharmaceuticals USA, Inc. | 6 | $202 |
| UCB, Inc. | 7 | $196 |
| Lundbeck LLC | 7 | $194 |
| Acadia Pharmaceuticals Inc | 7 | $193 |
| Neurocrine Biosciences, Inc. | 7 | $185 |
| Novartis | 6 | $172 |
| EMD Serono, Inc. | 5 | $166 |
| Pfizer | 9 | $158 |
| Argenx US, Inc. | 6 | $136 |
| Amgen | 6 | $123 |
| Otsuka America Pharmaceutical, Inc. | 5 | $110 |
| Lilly USA, LLC | 7 | $108 |
| Biogen | 4 | $100 |
| Genentech USA, Inc. | 5 | $96 |
| Eisai Inc. | 3 | $72 |
| Merz Pharmaceuticals, LLC | 3 | $68 |
| Catalyst Pharmaceuticals, Inc. | 3 | $64 |
| Kyowa Kirin, Inc. | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $46 |
| Neurelis, Inc. | 2 | $43 |
| Insightec,inc | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Cycle Pharmaceuticals Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,046 in reported general payments places this provider in the 80th percentile of 292 adult health providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 33 | $33,524 |
| QuliptaAtogepant | 23 | $28,212 |
| Nurtec OdtRimegepant Sulfate | 17 | $21,207 |
| Emgality PenGalcanezumab-Gnlm | 18 | $16,486 |
| NeuproRotigotine | 16 | $13,070 |
| Memantine Hcl | 170 | $7,720 |
| Levetiracetam | 88 | $2,621 |
| Donepezil Hcl | 177 | $2,424 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 83 | $2,420 |
| Lacosamide | 15 | $1,373 |
| Primidone | 31 | $1,253 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 26 | $1,135 |
| Carbamazepine | 13 | $1,112 |
| Topiramate | 45 | $897 |
| RizatriptanRizatriptan Benzoate | 24 | $805 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $792 | $61,73656 claims |
| PfizerNurtec Odt | $158 | $21,20717 claims |
| UCB, Inc.Neupro | $196 | $13,07016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 292 adult health providers in South Carolina.
Other adult health in West Columbia
- Andrea OlsonWest Columbia$12K
- Christi WigginsWest Columbia$10K
- Leslee AunWest Columbia$8K
- Susan GriffinWest Columbia$8K
- Jennifer PeaglerWest Columbia$8K
- Latoya HintonWest Columbia$7K
- Shannon HallmanWest Columbia$7K
- Natalie O'KellyWest Columbia$7K
- Haleigh TaylorWest Columbia$6K
- Cecilia PorcherWest Columbia$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.